Print Page  |  Close Window

Overview

BioTelemetry provides cardiac monitoring services, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services. Since the Company became focused on cardiac monitoring in 1999, the Company has developed a proprietary integrated patient management platform that incorporates a wireless data transmission network, Food and Drug Administration ("FDA") cleared algorithms and medical devices, and 24-hour digital monitoring service centers.

The Company operates under three segments: patient services, product and research services. The patient services segment is focused on the diagnosis and monitoring of cardiac arrhythmias, or heart rhythm disorders. The Company provides cardiologists and electrophysiologists who prefer to use a single source of cardiac monitoring services with a full spectrum of solutions, ranging from the differentiated Mobile Cardiac Outpatient TelemetryTM ("MCOT™") service to wEvent, event, Holter, Pacemaker and International normalized ratio ("INR") monitoring. INR monitoring is a measurement of blood coagulation in the circulatory system and is prescribed for patients on long term anticoagulation therapy. The product business segment focuses on the development, manufacturing, testing and marketing of medical devices to medical companies, clinics and hospitals. The research services segment is engaged in central core laboratory services providing cardiac monitoring, scientific consulting and data management services for drug and medical device trials.

Recent NewsMore >>
DateTitle 
05/15/19BioTelemetry President and CEO Joseph H. Capper Named Healthcare CEO of the Year at 26th Annual PACT Enterprise Awards
MALVERN, Pa., May 15, 2019 (GLOBE NEWSWIRE) -- BioTelemetry (NASDAQ:BEAT), the leading remote medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, today announced that Joseph H. Capper, President and CEO, has been awarded the 2019 Healthcare CEO of the Year Award by the Philadelphia Alliance for Capital and Technologies, or PACT. The Healthcare CEO of the Year Award recognizes leaders for their management accomplishment... 
Printer Friendly Version
04/25/19BioTelemetry, Inc. Reports First Quarter 2019 Financial Results
Achieves Record Quarterly Revenue Raises Full Year 2019 Guidance MALVERN, Pa., April 25, 2019 (GLOBE NEWSWIRE) -- BioTelemetry, Inc. (NASDAQ:BEAT), the leading remote medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, today reported results for the first quarter ended March 31, 2019. Quarter Highlights Recognized record quarterly revenue of $104.0 million Reached 10.0% year-over-year revenue growth Achiev... 
Printer Friendly Version
04/18/19BioTelemetry, Inc. to Release First Quarter 2019 Earnings Results on April 25, 2019
MALVERN, Pa., April 18, 2019 (GLOBE NEWSWIRE) -- BioTelemetry, Inc. (NASDAQ:BEAT) will release its first quarter 2019 earnings on Thursday, April 25 at 4:00 PM Eastern Time. The BioTelemetry quarterly conference call will be held at 5:00 PM Eastern Time, Thursday, April 25, 2019.  The broadcast will be available through the investor information section of the BioTelemetry website www.gobio.com.  If you are unable to participate during the live webcast, an archive will be available on our we... 
Printer Friendly Version
03/04/19BioTelemetry, Inc. Completes Acquisition of Geneva Healthcare, Inc.
MALVERN, Pa., March 04, 2019 (GLOBE NEWSWIRE) -- BioTelemetry, Inc. (NASDAQ:BEAT), the leading remote medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, announced today that the Company has completed its acquisition of Geneva Healthcare, Inc., the leading provider of remote monitoring for implantable cardiac devices. Joseph H. Capper, President and Chief Executive Officer of BioTelemetry, Inc., commented: “We are exci... 
Printer Friendly Version

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.